 Principia Biopharma NASDAQ:PRNB was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report issued on Saturday, Zacks.com reports. The brokerage presently has a 69.00 target price on the stock. Zacks Investment Researchs price objective would suggest a potential upside of 7.58 from the stocks previous close. According to ... 